Claim Ownershippharmaphorum Podcast
Subscribed: 45Played: 885
Subscribe
© 2022 Pharmaphorum
Description
pharmaphorum is one of the leading global channels for insight into the pharma and healthcare industry – and is essentially a group of passionate people who like asking excellent questions. Our podcasts offer a chance to pose some of these questions to the keenest minds in our industry to look at the big issues and opportunities facing pharma, biotech and healthcare today. With interviews and contributions from a host of industry experts and insiders, the pharmaphorum podcast is a must-listen for those who want insight into the future of health and medicine.
288 Episodes
Reverse
In the final episode of our special Frontiers Health limited series of the pharmaphorum podcast, web editor Nicole Raleigh speaks with the Chairman of Frontiers Health, Robert Ascione.
Ascione - a serial entrepreneur & thought leader in health innovation and digital health, global executive, CEO and founder of Healthware Group, and President of Health Innovation at EVERSANA – talks about his favourite memory from Frontiers Health, as well as how his work outside of the conference both informs and is informed by it. Finally, he contemplates what will define the future of health.
Listen to this and other episodes from the Frontiers Health limited series here.
As Gain Therapeutics announces positive Phase 1b results for its lead compound, GT-02287, pharmaphorum looks back to a conversation with the company’s CEO Gene Mack earlier in the year, discussing allosteric small molecule therapies in the Parkinson’s disease space.
Mack discusses the company’s progress in this field, and explores where next in terms of the unmet needs of Parkinson’s disease and the potential of this specific area of R&D in the future.
You can listen to episode 209a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
As one of Frontiers Health’s most recognisable faces (and voices), Jessica DaMassa, founder of WTF Health and long-time emcee of the conference, has had a front-row seat to the events evolution over the last decade.
In this episode of the pharmaphorum podcast’s special Frontiers Health anniversary series, DaMassa joins Deep Dive editor, Eloise McLennan, for a behind-the-scenes look at what it takes to run the show – both on and off stage. She reflects on her very first visit to Frontiers Health, her evolution from conference-floor reporter to main-stage moderator, and why flexibility, curiosity, and a healthy sense of humour are essential tools for interviewing some of the biggest names in healthcare.
A self-described “health tech gossip,” DaMassa shares what she’s most looking forward to at this year’s event, how she prepares for interviews with top leaders across pharma and digital health, and why hype doesn’t always equal impact when it comes to innovation.
Healthcare organisations are facing the simultaneous pressures of demonstrating ROI on AI investments, addressing clinician burnout, and satisfying compliance requirements.
In a new pharmaphorum podcast, Dr Jay Anders, chief medical officer for Medicomp Systems, and also host of the Tell Me Where IT Hurts podcast, discusses why he believes that the only way organisations can solve all three of those problems is by first solving data quality issues.
Anders talks about this data quality crisis, and the financial and operational impacts of the current situation, and explains why providers must ensure clinical data is validated, cleaned, and optimised.
You can listen to episode 208a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
The cell culture media industry is currently experiencing significant growth, driven by the increasing demand for biopharmaceuticals, advancements in tissue engineering, and the rising number of research activities in cell biology.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Brandon Pence, who was recently appointed President and COO of Fujifilm Biosciences, a company previously known as Fujifilm Irvine Scientific, about the cell culture media field.
Pence also discusses end-to-end life sciences capabilities to create an accelerated path toward greater patient access for advanced care, as well as the shift of late to the US for many large pharma, during Trump’s second administration.
You can listen to episode 207a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
This year marks the 10th anniversary of Frontiers Health.
In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with commercial strategy expert Pilar Fernández Hermida, founder of i-Expand, a commercial strategy firm focused on assisting Health Tech and Deeptech companies grow and monetise.
Fernández Hermida shares her favourite memory from the conference’s past decade, and discusses commercialisation of new technologies, such as advanced therapies and foundational tech like AI, and how CGTs can become more accessible, as well as much more.
Explore this Frontiers Health conversation and others - and find out how to attend the conference - here.
In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Anthony Cilento, vice president, data science & customer insights, at Bayer, in a post-Axtria Ignite 2025 discussion on the conference and agentic AI more generally.
Cilento speaks to the advancement from GenAI to agentic AI, what’s changed for his own team in this regard and what’s required by way of a culture shift more generally, as well as speaking to the changes necessary in the advanced therapies space when it comes to commercialisation.
You can listen to episode 206a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
This year marks the 10th anniversary of Frontiers Health.
In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with founder, director, and global health advisor at D-Health Consulting, Roberta Sarno. Sarno is also director of the APAC Liver Disease Alliance, and consultant on digital health APAC policy at the American Telemedicine Association, as well as advisor to the Asia Pacific Medical Technology Association.
Sarno discusses her favourite memory from Frontiers Health, as well as the importance of equity and accessibility for patients, and how that needs to be from day one. The conversation also touches upon the rural community experience, and explores global health innovation more widely, Sarno explaining why multistakeholder involvement is key.
Explore this Frontiers Health conversation and others - and find out how to attend the conference - here.
This year marks the 10th anniversary of Frontiers Health.
In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with healthcare innovation consultant Gary Monk.
Monk shares his favourite memory from the conference’s past decade, and discusses its ethos, as well as how his work at the moment aligns with that.
Explore this Frontiers Health conversation and others - and find out how to attend the conference - here.
Frontiers Health marks its 10th anniversary this year, celebrating a decade of innovation, collaboration, and the connections that drive progress.
In this episode of our Frontiers Health limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Aline Noizet, founder of Digital Health Connector – a phrase that she says encapsulates both her personal mission and her 15 years of experience in the industry.
Noizet has built her career on connecting emerging start-ups with the partners who can help them grow, with the goal of ensuring that digital health solutions reach the patients who need them most. For her, Frontiers Health is about more than just ideas – it is about the relationships that make innovation possible.
Here, she reflects on the importance of creating these connections, the unique atmosphere of Frontiers Health, and some of her favourite moments from the past decade.
In Donald Trump's first presidential term, he spoke a lot about "Most Favoured Nations" pricing for pharmaceuticals - that is, bringing the prices that Americans pay for drugs in line with prices paid around the world. In his first term, all that talk didn't amount to much. But this time around the pharma industry is taking the President much more seriously.
In today's pharmaphorum podcast, host Jonah Comstock speaks with Alice Valder Curran, a partner at Hogan Lovells and our go-to expert on US policy in pharma, for an update on what's happening right now with Most Favoured Nations drug pricing.
Curran brings us up to speed on what's happened with the President's Executive Order and the industry response so far, then she and Comstock break down what was in the recent letters sent by the administration to major pharma companies and subsequently posted on Truth Social by the President.
They talk about the short-term and long-term impacts of the policy, to what extent it's likely to come to fruition, and to what extent the industry has already begun to change its behaviour in response. Check out the full episode below to learn more about what could be the most impactful US policy change for pharma's bottom line in decades.
Frontiers Health is back, and celebrating 10 years of innovation, conversation, and collaboration.
In this episode of our Frontiers Health limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Denise Silber, founder of Basil Strategies and Doctors 2.0.
Having spent more than two decades working at the intersection of healthcare professionals, patients, and technology, Silber has had a front row seat to the evolution of digital tools in the sector. From the early adoption of electronic health records to the integration of new artificial intelligence, she has witnessed dramatic shifts across life sciences, yet at the heart of her work remains the core focus of patient centricity.
In this interview, she discusses the importance of spotlighting patient centricity at Frontiers Health, what makes the event special, and her favourite moments from years gone by.
Chronic myeloid leukaemia (CML) is a unique disorder in the rare disease sector because there are multiple approved therapies for patients and, in the US alone, the prevalence of CML is expected to triple by 2040.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Amy Burroughs, CEO of Terns Pharmaceuticals, about available treatments for CML, the potential of allosteric TKIs, and the wider oncological landscape today.
You can also listen to episode 205a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
In this episode of our Frontiers Health limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital.
Seuntjens has long been focused on investing in innovation that puts the individual at the centre of health. For him, building companies is never easy – but it becomes meaningful when the outcome is more engaged people, improved health results, and ultimately reduced costs. That, he believes, is where the true value of healthcare transformation lies.
He also shares some of his favourite moments from Frontiers Health, where ideas, energy, and people come together to push the boundaries of what’s possible in personal health innovation.
When it comes to breaking down barriers, humour is vitally important, helping to do away with stigma when it comes – in particular – to pharma and health advertising.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Brian Coane, health partner at creative agency Leith, who talks sensitivity, maximum impact, and overcoming the fear of getting it wrong.
After all, dull ads can lead to the dreaded ‘beige tax’.
You can also listen to episode 204a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
Biotech finance has encountered what can arguably be termed the worst perfect storm in its history, and private investment in biopharma is in the midst of the longest drought.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with former surgeon and investment banker Ali Pashazadeh, CEO of Treehill, a strategic and financial advisory firm for the life sciences sector, in a conversation focused on the current ‘perfect storm’ in biotech and why the skies might not be quite as grey and foreboding as at first feared.
Pashazadeh discusses how developers, CDMOs, CROs, and all other companies involved in therapeutic development might have to adjust to this new world.
You can also listen to episode 203a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
This year marks the 10th anniversary of Frontiers Health.
In this episode of our Frontiers Health limited series of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Unity Stoakes, president and co-founder of Startup Health and Advisory Board Member at The NeuroTech Collider Lab, University of California, Berkeley.
Stoakes has spent 30+ years at the intersection of tech, science, and design, operating with the focal goal of transforming global health. And Frontiers Health provides a buzz, a magic, and a vibe to attain that.
For Stoakes, Frontiers Health is all about the people, and the space; spaces selected especially to promote meaningful networking. Thereby leveraging network effects, exploring and progressing the power of innovation, and the power indeed of entrepreneurs to build together and bring change to beneficially affect people’s wellbeing globally – for Stoakes, today is one of the most exciting times in history to change the trajectory of health.
Listen to this special Frontiers Health episode of the pharmaphorum podcast to learn more about the big challenges that need to be solved for humanity, and discussion of the future landscape of human health.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Hilary Eaton, a rare disease advocate and chief business officer at Profluent about AI-first protein design and its part in accelerating biomedicine.
Eaton discusses her advocacy, gene editing, and how real-world evidence shows that AI scaling laws – which predict model performance based on size and computing power – apply to biology.
You can also listen to episode 202a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
Characterising the behaviour of drugs in humans has historically required extensive clinical trials at considerable time and cost. So, any lab-derived early insight into how drugs will behave in human patients can make drug trials vastly more efficient.
In this episode, the pharmaphorum podcast welcomes Adityo Prakash, founder and CEO of Verseon, a clinical-stage pharmaceutical company based in Fremont, California that is developing several drug discovery programmes in cardiometabolic diseases and cancer using molecular physics and artificial intelligence.
Prakash discusses development of new AI technologies to handle the small, sparse datasets typical of real-world scenarios, and how testing drugs on organoids – artificially grown masses of cells that resemble the function of specific human organs – can deliver valuable information on the potential effects of drugs in real patients before any human is dosed.
You can also listen to episode 201a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
This November marks a major milestone for health innovation as Frontiers Health celebrates its 10th anniversary.
To mark the occasion, pharmaphorum is proud to launch a special limited-edition podcast series, bringing you conversations with the people who’ve helped define the conference over the years – and those driving the next wave of innovation.
We’re kicking things off with a very special guest: Kristin Milburn, SVP, marketing ecosystem & strategy at Frontiers Health. Having served across several roles – both on and off stage – she offers a rare perspective on what makes the conference so unique, and what attendees can expect from this special anniversary event.
Tune in to this Frontiers Health special of the pharmaphorum podcast for exclusive insights, memorable stories, and expert perspectives from the driving force at the heart of it all, and be sure to subscribe to catch the rest of the series as we count down to the 10th anniversary edition of Frontiers Health this November.
Comments
Download from Google Play
Download from App Store
United States